Aurinia Pharmaceuticals Inc Ordinary Shares (AUPH)
Stock · NASDAQ · Health Care
$16.51as of 10/16/2026
Price chart
Active signals
AUPH Signal Track Record
How signals performed across all stocks →What AUPH's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 34 | +2.4% | 59% | September 8, 2026 |
| Bollinger Band Breakout | 27 | -1.3% | 44% | August 19, 2026 |
| Bollinger Band Breakdown | 17 | -0.1% | 47% | April 29, 2026 |
| 200-Day Moving Average TouchActive now | 10 | +8.5% | 80% | October 6, 2026 |
| Any 20-session window (baseline) | +0.5% | 52% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About AUPH
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducin…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 128
- Website
- www.auriniapharma.com
Fundamentals
- 1-day range
- $16.35$16.81
- Market cap
- $2.10B
- P/E (trailing)
- 7.11
- P/E (forward)
- 15.48
- EPS (trailing)
- $2.29
- Dividend yield
- —
- Beta
- 1.35
- Avg. volume
- 972.6K
How Aurinia Pharmaceuticals Inc Ordinary Shares Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 26, 2026 · via SEC EDGAR / Finnhub
Forecasts
7 analyst ratings
Aurinia Pharmaceuticals Inc Ordinary Shares Competitors
Chosen by industry and closest market cap.
- AUPHAurinia Pharmaceuticals Inc Ordinary Shares$16.51▼ 1.31%Market cap $2.10BP/E 7.11$11.21$19.25
- GHRSGH Research PLC Ordinary Shares$18.15▼ 3.51%Market cap $2.10BP/E —$12.04$31.44
- NUVBNuvation Bio Inc. Class A Common Stock$4.45▼ 6.32%Market cap $2.13BP/E —$3.36$9.75
- HCMHUTCHMED (China) Limited American Depositary Shares$14.05▲ 0.79%Market cap $2.06BP/E 133.15$15.57$26
- STOKStoke Therapeutics Inc. Common Stock$24.17▼ 1.79%Market cap $2.06BP/E —$20.32$40.22
- ZBIOZenas BioPharma Inc. Common Stock$24.84▼ 2.20%Market cap $2.03BP/E —$13.5$44.6
- BHVNBiohaven Ltd. Common Shares$10.78▼ 5.69%Market cap $2.17BP/E —$7.48$18.57
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| AUPH Aurinia Pharmaceuticals Inc Ordinary Shares | $2.10B | 7.11 | $16.51 | ▼ 1.31% | $11.21$19.25 |
| GHRS GH Research PLC Ordinary Shares | $2.10B | — | $18.15 | ▼ 3.51% | $12.04$31.44 |
| NUVB Nuvation Bio Inc. Class A Common Stock | $2.13B | — | $4.45 | ▼ 6.32% | $3.36$9.75 |
| HCM HUTCHMED (China) Limited American Depositary Shares | $2.06B | 133.15 | $14.05 | ▲ 0.79% | $15.57$26 |
| STOK Stoke Therapeutics Inc. Common Stock | $2.06B | — | $24.17 | ▼ 1.79% | $20.32$40.22 |
| ZBIO Zenas BioPharma Inc. Common Stock | $2.03B | — | $24.84 | ▼ 2.20% | $13.5$44.6 |
| BHVN Biohaven Ltd. Common Shares | $2.17B | — | $10.78 | ▼ 5.69% | $7.48$18.57 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Aurinia: Lupkynis Is A Cash Cow, But Competition And Patent Risks Cap The UpsideSeekingAlpha · 9/22/2026
- Aurinia’s (AUPH) Profits Surge While Its One Drug Just Got CompanyYahoo · 9/16/2026
Insider Activity
Insider Actions →- Stephen P. Robertson · September 10, 2026 · Sale11.9K @ $15.95
- Stephen P. Robertson · August 21, 2026 · Sale21.0K @ $16.97
- Kathleen Goetz · June 4, 2026 · Grant23.9K
- Jeffrey Allen Bailey · June 4, 2026 · Grant23.9K
- Craig A. Johnson · June 4, 2026 · Grant23.9K
- Nova Tina Susan · June 4, 2026 · Grant23.9K
- TANG KEVIN · June 2, 2026 · J10.0K @ $1.65
- TANG KEVIN · June 2, 2026 · Buy206.0K @ $15.28
- TANG KEVIN · June 1, 2026 · Buy99 @ $15.34
- TANG KEVIN · June 1, 2026 · Buy343.5K @ $15.28
- TANG KEVIN · May 29, 2026 · Buy262.7K @ $15.31
- TANG KEVIN · May 29, 2026 · Buy2.3K @ $15.35
- Ryan Cole · May 18, 2026 · Grant70.2K
- Stephen P. Robertson · May 18, 2026 · Grant115.5K
- Ryan Cole · May 18, 2026 · Grant116.1K
Institutional Ownership
March 31, 2026
- Total shares held
- 72.77M
- Total value held
- $1.05B
- Institutional holders
- 253
- Unknown12.23M
- Unknown7.85M
- Unknown3.97M
- Unknown3.43M
- Unknown3.28M
- Unknown2.53M
- Unknown2.23M
- Unknown1.87M
- Unknown1.66M
- Unknown1.57M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
AUPH Appears in Report on Activist Investor Activity
Aurinia Pharmaceuticals was mentioned among stocks drawing attention from activist investors, according to recent financial news coverage. No specific activist involvement details or corporate action plans were detailed in the report. The stock is currently trading between its 52-week range extremes, with analysts maintaining price targets notably above current levels.
AUPH Appears in Report on Activist Investor Activity. Aurinia Pharmaceuticals was mentioned among stocks drawing attention from activist investors, according to recent financial news coverage. No specific activist involvement details or corporate action plans were detailed in the report. The stock is currently trading between its 52-week range extremes, with analysts maintaining price targets notably above current levels.